RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Medlab Clinical Stock

Medlab Clinical ROE 2025

Medlab Clinical ROE

2.5

Ticker

MDC.AX

ISIN

AU000000MDC8

WKN

A14R7W

In 2025, Medlab Clinical's return on equity (ROE) was 2.5, a -147.28% increase from the -5.3 ROE in the previous year.

Medlab Clinical Aktienanalyse

What does Medlab Clinical do?

Medlab Clinical Ltd is an innovative biotechnology company focused on the development and commercialization of medical products and services. The company was founded in Australia in 2012 and is now based in Sydney. Since its founding, Medlab has established itself as a leading provider of diagnostic and therapeutic products. Medlab's business model consists of three different divisions. The first division is pharmaceutical development, where Medlab works on the development of new medications for the treatment of conditions such as fibromyalgia, pain, or ADHD. Medlab is particularly innovative in the development of medications based on the use of cannabinoids that are approved for medical use. The second division of Medlab is the research and development of nutritional supplements. The company works on the development of innovative products to improve general well-being and support health. An example is the nutritional supplement NRGBiotic, which contains special probiotic bacteria that help regulate the intestinal flora and thereby strengthen the immune system. The third division of Medlab is clinical diagnostics. The company offers various medical diagnostic tests, such as the test for food intolerances. This test is based on a blood sample and allows for targeted dietary changes in individuals with intolerance. Medlab aims to improve people's lives by developing and providing innovative products and services for medical care. Medlab's products are designed to promote the health and well-being of patients and customers and improve their quality of life. One outstanding product from Medlab is NanoCBD, an innovative form of cannabinoid delivery for medical purposes. The advantage of NanoCBD is that it has increased bioavailability due to the nanoparticles, resulting in faster and more effective action than conventional CBD products. Another product from Medlab is the pain medication NanaBis, which works faster and more effectively than other pain medications due to its unique formulation. Thanks to its special composition, NanaBis can also be taken by patients with severe chronic pain who do not respond to other pain medications. Medlab has established itself as a global company and is present worldwide. The company maintains partnerships and collaborations with renowned research institutions and doctors in Europe, North America, Australia, and Asia. Medlab works closely with medical professionals to ensure that the company's products and services meet the highest quality standards and meet the needs of patients and customers. Overall, Medlab Clinical Ltd has established itself as an innovative and reliable company in the medical industry. With its clear focus on the development of innovative medications, nutritional supplements, and diagnostic systems, Medlab significantly contributes to improving the healthcare system and increasing the well-being of people worldwide. Medlab Clinical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Medlab Clinical's Return on Equity (ROE)

Medlab Clinical's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Medlab Clinical's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Medlab Clinical's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Medlab Clinical’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Medlab Clinical stock

What is the ROE (Return on Equity) of Medlab Clinical this year?

The ROE of Medlab Clinical this year is 2.5 undefined.

How has the Return on Equity (ROE) of Medlab Clinical developed compared to the previous year?

The ROE of Medlab Clinical has increased by -147.28% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Medlab Clinical?

A high ROE indicates that Medlab Clinical generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Medlab Clinical?

A low ROE can indicate that Medlab Clinical is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Medlab Clinical affect the company?

A change in ROE (Return on Equity) of Medlab Clinical can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Medlab Clinical?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Medlab Clinical?

Some factors that can influence Medlab Clinical's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Medlab Clinical pay?

Over the past 12 months, Medlab Clinical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Medlab Clinical is expected to pay a dividend of 0 AUD.

What is the dividend yield of Medlab Clinical?

The current dividend yield of Medlab Clinical is .

When does Medlab Clinical pay dividends?

Medlab Clinical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Medlab Clinical?

Medlab Clinical paid dividends every year for the past 0 years.

What is the dividend of Medlab Clinical?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Medlab Clinical located?

Medlab Clinical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Medlab Clinical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Medlab Clinical from 8/6/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 8/6/2025.

When did Medlab Clinical pay the last dividend?

The last dividend was paid out on 8/6/2025.

What was the dividend of Medlab Clinical in the year 2024?

In the year 2024, Medlab Clinical distributed 0 AUD as dividends.

In which currency does Medlab Clinical pay out the dividend?

The dividends of Medlab Clinical are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Medlab Clinical

Our stock analysis for Medlab Clinical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medlab Clinical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.